TCGA-OR-A5KU-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.345
- GLYCOLYSIS+0.311
- UNFOLDED_PROTEIN_RESPONSE+0.296
- HYPOXIA+0.273
- HEDGEHOG_SIGNALING+0.220
- BILE_ACID_METABOLISM+0.187
- ANDROGEN_RESPONSE+0.133
- INTERFERON_GAMMA_RESPONSE+0.118
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.095
- IL2_STAT5_SIGNALING+0.051
Top 10 suppressed
- E2F_TARGETS-0.354
- G2M_CHECKPOINT-0.352
- OXIDATIVE_PHOSPHORYLATION-0.332
- MITOTIC_SPINDLE-0.321
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- MYC_TARGETS_V1-0.295
- ALLOGRAFT_REJECTION-0.283
- COMPLEMENT-0.261
- PI3K_AKT_MTOR_SIGNALING-0.223
- FATTY_ACID_METABOLISM-0.218
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02146 | — | cohortA1 | 0.653 |
| 2 | e32633c0-5ccc-47a9-bd67-60d3c022dfc9 | — | — | 0.630 |
| 3 | MDT-AP-0760 | Med | Medulloblastoma | 0.619 |
| 4 | MDT-AP-2072 | Med | Medulloblastoma | 0.616 |
| 5 | MDT-AP-2031 | Med | Medulloblastoma | 0.608 |
| 6 | C3N-03890 | — | cohortA1 | 0.603 |
| 7 | SRR661005 | GTEX | — | 0.590 |
| 8 | SRR8613702 | — | C | 0.585 |
| 9 | SRR13311156 | — | — | 0.584 |
| 10 | X21fbbe96.619e.4fba.9a39.8f9098cb173e | — | cohortA1 | 0.584 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.345 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.311 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.296 | Idelalisib | — uncovered |
| HYPOXIA | 0.273 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.187 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.133 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.118 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.095 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.051 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.042 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.039 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.024 | Remibrutinib | — uncovered |
| PEROXISOME | 0.006 | Idelalisib | — uncovered |